Compare Annaly Capital Management, Inc. (NLY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs TG Therapeutics Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.9 (market cap $16.63B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Annaly Capital Management, Inc. is far larger — about 2× TG Therapeutics Inc's market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NLY | TGTX | |
|---|---|---|
Market Cap | $16.63B | $8.26B |
Sector | Financials | Health |
52-Week High | $24.40 | $59.06 |
52-Week Low | $19.96 | $26.39 |
Dividend Yield | 13.22% | — |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
